Riassunto
L’androgenizzazione cutanea femminile, espressa da iperseborrea, acne, ipertricosi e defluvium capitis, è determinata da un’iperstimolazione dell’apparato pilo-sebaceo da parte degli androgeni. Può essere idiopatica o sintomatica ed è efficacemente trattata con farmaci ad attività antiandrogena. In questa rassegna vengono illustrate le molecole dotate di attività antiandrogena, il loro meccanismo d’azione, gli effetti collaterali e gli schemi terapeutici più maneggevoli ed efficaci utilizzabili nella pratica clinica.
Bibliografia
Rosenfield RL. Pilosebaceous physiology in relation to hirsutism and acne. Clin Endocrinol Metab 15: 341, 1986.
Zachmann M, Prader A. Anabolic and androgenic effect of testosterone in sexually immature boys and its dependency on growth hormone. J Clin Endocrinol Metab 30: 85, 1970.
Gafny M, Silbergeld A, Klinger B, Wasserman M, Laron Z. Comparative effects of GH, IGF-I and insulin on serum sex hormone binding globulin. Clin Endocrinol 41: 169, 1994.
Oakes SR, Haynes KM, Waters MJ, Herington AC, Werther GA. Demonstration and localization of growth hormone receptor in human skin and skin fibroblasts. J Clin Endocrinol Metab 75: 1368, 1992.
Toscano V, Sciarra F, Adamo MV, Petrangeli E, Foli S, Caiola S, Conti C. Is 3α-androstanediol a marker of peripheral hirsutism? Acta Endocrinol 99: 314, 1982.
Lobo R, Goebelsmann U, Horton R. Evidence for the importance of peripheral tissue events in the development of hirsutism of polycystic ovary syndrome. J Clin Endocrinol Metab 57: 393, 1983.
Toscano V, Balducci R, Bianchi P, Guglielmi R, Mangiantini A, Rossi FG, Colonna LM, Sciarra F. Two different pathogenetic mechanisms may play a role in acne and in hirsutism. Clin Endocrinol 39: 551, 1993.
Imperato-McGinley J, Gautier T, Cai L, Yee B, Epstein J, Pochi P. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab 76: 524, 1993.
Hammerstein J, Cupceancu B. Behandlung des Hirsutismus mit Cyproteronacetat. Dtsch Med Wochenschr 94: 829, 1969.
Molinatti GM, Messina M, Manieri C, Massucchetti C, Biffignandi P. Current approaches to the treatment of virilizing syndromes. In: Molinatti GM, Martini L, James VHT (Eds.) Androgenization in women. Raven Press, New York, 1983, p 179.
Fruzzetti F, Bersi C, Parrini D, Ricci C, Genazzani A.R. Treatment of hirsutism: comparison between different antiandrogens with central and peripheral effects. Fertil Steril 71: 445, 1999.
Kelestimur F. Diane 35 and spironolactone combination in the treatment of hirsutism. Clin Endocrinol 54: 699, 2001.
MILTS. Oral contraceptives and liver cancer. Results of the Multicentre International Liver Tumor Study (MILTS). Contraception 56: 275, 1997.
Basinger GT, Gitte RB. Antiandrogenic effect of spironolactone in rats. J Urol 111: 77, 1974.
Shapiro G, Evron S. A novel use of spironolactone: treatment of hirsutism. J Clin Endocrinol Metab 51: 429, 1978.
Spritzer PM, Lisboa KO, Mattiello S, Lhullier F. Spironolactone as a single agent for long-term therapy of hirsute patients. Clin Endocrinol 52: 587, 2000.
Messina M, Manieri C, Musso MC, Pastorino R. Oral and topical spironolactone therapies in skin androgenization. Panminerva Med. 32: 1, 1990.
Moghetti P, Tosi F, Tosti A, Negri C, Misciali C, Perrone F, Caputo M, Muggeo M, Castello R. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab 85: 89, 2000.
Ibáñez L, Potau N, Marcos MV, de Zegher F. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism in nonobese, adolescent girls: effect of flutamide. J Clin Endocrinol Metab 85: 3251, 2000.
Muderris II, Bayram F. Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest 22: 165, 1999.
Vigersky RA, Mehlman I, Glass AR, Smith CE. Treatment of hirsute women with cimetidine. N Engl J Med 303: 1042, 1980.
Cilotti A, Danza G, Serio M. Clinical application of 5a-reductase inhibitors. J Endocrinol Invest 24: 199, 2001.
Fruzzetti F, de Lorenzo D, Parrini D, Ricci C. Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women. J Clin Endocrinol Metab 79: 831, 1994.
Manieri C, Grosso T, Di Bisceglie C, Fornengo R, Tagliabue M, Martina V, Taliano M, Bertagna A. Finasteride in idiopathic hirsutism: its effectiveness in blocking 5α-reductase. Int J Immunopathol Pharmacol 10: 139, 1997.
Sahin Y, Dilber S, Kelestimur F. Comparison of Diane 35 and Diane 35 plus finasteride in the treatment of hirsutism. Fertil Steril 75: 496, 2001.
Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae K.D. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 312: 83, 1996.
Fruzzetti F, Ricci C, Fioretti P. Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives. Contraception 49: 579, 1994.
Conn JJ, Jacobs HS. Managing hirsutism in gynaecological practice. Br J Obstet Gynaecol 105: 687, 1998.
Escobar-Morreale HF, Lasuncion MA, Sancho J. Treatment of hirsutism with ethinyl estradiol-desogestrel contraceptive pills has beneficial effects on the lipid profile and improves insulin sensitivity. Fertil Steril 74: 816, 2000.
Harvengt C. Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus. Diabetes Metabolism 18: 71, 1992.
Pascale M-M, Pugeat M, Roberts M, Rousset H, Déchaud H, Dutrieux-Berger N, Tourniaire J. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours. Clin Endocrinol 41: 571, 1994.
Manieri C, Di Bisceglie C, Fornengo R, Grosso T, Zumpano E, Calvo F, Berardengo E, Volante M, Papotti M. Postmenopausal virilization in a woman with gonadotropin dependent ovarian hyperthecosis. J Endocrinol Invest 21: 128, 1998.
Efstathiadou Z, Tsatsoulis A. Long-term remission of ovarian hyperandrogenism after short-term treatment with a gonadotropin-releasing hormone agonist. Fertil Steril 75: 59, 2001.
Andreyko JL, Monroe SE, Jaffe RB. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (Nafarelin). J Clin Endocrinol Metab 63: 854, 1986.
Carmina E, Lobo RA. Gonadotrophin-releasing hormone agonist therapy for hirsutism is as effective as high dose cyproterone acetate but results in a longer remission. Human Reprod 12: 663, 1997.
Vidal-Puig AJ, Munoz-Torres M, Jodar-Gimeno E, Garcia-Calvente CJ, Lardelli P, Ruiz-Requena ME, Escobar-Jimenez F. Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol 130: 333, 1994.
Negri C, Tosi F, Dorizzi R, Fortunato A, Spiazzi GG, Muggeo M, Castello R, Moghetti P. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab 85: 81, 2000.
Kokaly W, McKenna TJ. Relapse of hirsutism following long-term successful treatment with oestrogen-progestogen combination. Clin Endocrinol 52: 379, 2000.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Manieri, C., Di Bisceglie, C., Tagliabue, M. et al. Terapia dell’androgenizzazione cutanea nella donna. L’Endocrinologo 2, 110–118 (2001). https://doi.org/10.1007/BF03344394
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03344394